WEDNESDAY, June 22 (HealthDay News) -- The treatment of pediatric obstructive sleep apnea syndrome (OSAS) with fluticasone furoate nasal spray may reduce secretions of interleukin 6 (IL-6), according to a study published in the June issue of the Archives of Otolaryngology -- Head & Neck Surgery.
Rania Esteitie, M.D., from the University of Chicago, and colleagues investigated the impact of intranasal corticosteroid therapy on T-regulatory cells and other inflammatory cytokines in the adenoid tissues of 24 children with OSAS. Children aged 2 to 12 years who were to undergo adenotonsillectomy for OSAS, were randomly allocated to receive treatment with 55 µg/nostril daily of fluticasone furoate nasal spray for two weeks before surgery (11 children), or no treatment (13 children). During the procedure, adenoid tissue was sampled. The main outcome measure was the number of tissue T-regulatory cells, as determined by staining with FOXP3, CD4, and CD25. Secondary outcomes included spontaneous and induced release of cytokines (IL-10, IL-6, IL-12, IL-13, tumor necrosis factor, and transforming growth factor β).
The investigators found that significantly less IL-6 was released spontaneously and on stimulation with anti-CD3 monoclonal antibody in the cells extracted from adenoid tissues treated with fluticasone furoate nasal spray compared with untreated adenoid tissue. The staining intensity for IL-10 was comparable between the groups. No significant differences were found in the number of CD4/FOXP3-, CD25/FOXP3-, or transforming growth factor β-positive cells.
"In this study, we show reduction of IL-6, a proinflammatory cytokine, in adenoid tissue obtained from children with OSAS treated with fluticasone furoate nasal spray," the authors write.
Abstract
Full Text (subscription or payment may be required)
